BsABN-501

N/A

Report date: 2026/03/19 17:11:52

Base Information

Drug NameBsABN-501

Drug Alias NameBsABN501BsABN-501

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > T cell engagers

Mechanisms of ActionAnti-Claudin-3T cell surface glycoprotein CD3 bindersT lymphocytes stimulants +[4]

TargetsClaudin-3T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbion Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbion Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A